Thor Explorations remains Canaccord Genuity (TSX:CF, LSE:CF)’s top London gold producer pick after posting its first quarter 2023 operational update, with the miner reporting the production of 20,629 ounces of gold at its Segilola mine in Nigeria.
In a note to clients, Canaccord analysts reiterated their ‘Buy’ rating for the stock and price target of 35p. Thor’s London-listed shares are currently trading at 19p.
Peel Hunt reiterated its 'buy' recommendation and a 524p per share price target for Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) following the latest update from its phase I/II trial of the lead asset, a cancer drug called bexmarilimab.
The broker noted that one of the highlights of Monday's announcement was the drug's apparent ability to ignite an immune response in a patient who wasn't previously responding to the standard of care treatment, azacytidine.
Anglo Asian Mining PLC (AIM:AAZ, OTC:AGXKF) said it produced 10,969 gold equivalent ounces from its operations in Azerbaijan during the three months to 31 March 2023.
Copper production increased by 49% year-on-year to 847 tonnes.
Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) produced 20,629 ounces of gold from its Segilola mine in Nigeria during the three months to end of March.
The average grade of the gold produced was 2.95 grammes per tonne.
Mosman Oil and Gas Ltd (AIM:MSMN) has told investors that the Arco-Fee G-1 (G1) well at Cinnabar, one of the field’s prior wells, has now flowed oil again following a well workover programme.
The company, in a statement, said that a workover involving gas injection has yielded results, with the well starting to flow and it will now be optimised by the addition of gas compression which will support pressure in the well.
Ondine Biomedical Inc (AIM:OBI) said it has made significant progress in preparing for its phase III clinical study to support the commercialisation of its Steriwave antimicrobial technology in the US.
The goal is to initiate the key trial in the second half of the year.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) has provided investors with encouraging additional phase I/II data on its cancer drug candidate, bexmarilimab.
The treatment is being tested in combination with standard treatments for patients with relapsed or unresponsive acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy specialist, has flagged a potential new use of its technology at the American Association for Cancer Research (AACR) annual meeting in Orlando, Florida, via a poster presentation.
The study demonstrated the potential of combining two different tests, immunofluorescent (IF) staining and HER2 fluorescence in-situ hybridisation (FISH) analysis, with cancer cells collected from the blood using ANGLE's Parsortix system.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has the green light from the Human Research Ethics Committee (HREC) to start its Phase 1/2 intravenous (IV) clinical trial of its lead pipeline compound RECCE® 327 (R327) in healthy male and female subjects.
The trial will look at assessing R327 as an intravenous dose at faster infusion rates (15 minutes and 30 minutes) across roughly 12 participants in three cohorts.